Axicabtagene Ciloleucel (Axi-Cel) versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7, A Phase 3, Randomized Study
Year: 2018
Type: article
Authors: Olalekan O. Oluwole, Michael R. Bishop, Christian Gisselbrecht, Leo I. Gordon, Marie José Kersten, David G. Maloney, Norbert Schmitz, Maria Dolores Caballero, John Kuruvilla, Kevin W. Song, Caron A. Jacobson, Loretta J. Nastoupil, Peter Riedell, Yizhou Jiang, John M. Rossi, Lillian Lee, Paul Cheng, Frederick L. Locke
Institutions: Vanderbilt University, Vanderbilt-Ingram Cancer Center, University of Chicago, Hôpital Saint-Louis, Northwestern University, Amsterdam UMC Location University of Amsterdam, University of Amsterdam, Fred Hutch Cancer Center, University Hospital Münster, Princess Margaret Cancer Centre, University of British Columbia, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Kite (United States), Moffitt Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2889021455